EFC5935: A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

The following study has recently been activated for patient enrollment by The University of Illinois Cancer Center Clinical Trials Office (CTO). Clink on the link to learn about the details regarding the study on clinicaltrials.gov.

For more information or questions about a study, email cancertrials@uic.edu or call 312-355-5112.

EFC5935: A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

https://clinicaltrials.gov/ct2/show/NCT04478266

Sponsor: Sanofi
Principal Investigator: Oanu Danciu, MD